TUESDAY, NOV 13, 8:00 AM

We will begin an amazing conference with Dr. Steven Nissen.

Steven E. Nissen

Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic

Steven E. Nissen MD is Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In 2006-2007 he served as President of the American College of Cardiology (ACC), the professional society representing American cardiologists.


TUESDAY, NOV 13, 1:30 PM

Randy J. Seeley

Henry King Ransom Endowed Professor of Surgery

Dr. Randy Seeley is the Henry K. Ransom Endowed Professor of Surgery at the University of Michigan School of Medicine. He also serves as the director of the NIH-funded Michigan Nutrition Obesity Research Center (MNORC). His scientific work has focused on the actions of various peripheral hormones in the CNS that serve to regulate food intake, body weight and the levels of circulating fuels.



Daniel J. Drucker, MD

Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital

Dr. Drucker received his MD from the University of Toronto in 1980, and is currently Professor of Medicine and the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology at the University of Toronto, and a Senior Scientist at the Lunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital. His laboratory studies the molecular biology and physiology of gut hormones with a focus on the glucagon-like peptides. Dr. Drucker and colleagues were the first to publish that GLP-1(7-37) directly augments glucose-dependent insulin biosynthesis and secretion from β cells, creating a foundation for decades of research in the diabetes and obesity field. His work has revolutionized pharmaceutical developments that have offered enormous benefits for diabetes, obesity and short bowel syndrome.

Glucagon-like peptide-1 exerts peripheral and central actions that control metabolic pathways, appetite, body weight and glucose homeostasis. GLP-1 exerts its actions through a canonical receptor widely expressed in the islets, central and peripheral nervous system and in the heart. Notably, GLP-1R agonists approved for the treatment of diabetes have demonstrated cardiovascular safety, and in some instances, reduced cardiovascular death in outcome studies. This keynote will discuss relevant sites and mechanisms of GLP-1 action, with clinical implications for the treatment of metabolic disease.

More information to follow.